(Total Views: 514)
Posted On: 11/05/2024 9:00:56 AM
Post# of 147996
Yes they do. Unreal & the last SH Letter:
In addition to CRC, CytoDyn is investigating the role for leronlimab in two other oncology indications via strategic and low-cost research and development opportunities,
( excerpt from Dr. Yam's bio --- He is the principal investigator for several industry sponsored and investigator initiated clinical trials."
Maybe he works on some industry funding for us too )
"....and in collaboration with several reputable institutions. I am pleased to announce that CytoDyn is working with a team of experts to resume the exploration of Triple-Negative Breast Cancer (“TNBC”), including colleagues from the University of Hawaii Cancer Center, MD Anderson Cancer Center, and the Pennsylvania Cancer and Regenerative Medicine Research Center. We will be working with this team in the coming months to design and conduct a preclinical TNBC study that will aim to confirm the mechanism of action of leronlimab in oncology..."
Yea, but we didn't expect any of them to directly jump on board @ Cytodyn.
Building the forward team(s) for Max.
Good stuff....
In addition to CRC, CytoDyn is investigating the role for leronlimab in two other oncology indications via strategic and low-cost research and development opportunities,
( excerpt from Dr. Yam's bio --- He is the principal investigator for several industry sponsored and investigator initiated clinical trials."
Maybe he works on some industry funding for us too )
"....and in collaboration with several reputable institutions. I am pleased to announce that CytoDyn is working with a team of experts to resume the exploration of Triple-Negative Breast Cancer (“TNBC”), including colleagues from the University of Hawaii Cancer Center, MD Anderson Cancer Center, and the Pennsylvania Cancer and Regenerative Medicine Research Center. We will be working with this team in the coming months to design and conduct a preclinical TNBC study that will aim to confirm the mechanism of action of leronlimab in oncology..."
Yea, but we didn't expect any of them to directly jump on board @ Cytodyn.
Building the forward team(s) for Max.
Good stuff....
(8)
(0)Scroll down for more posts ▼
